The results of a comparative study effectiveness of therapy with nebivolol and sotalol in patients with ventricular arrhythmias.

Aim. Compare the effectiveness of nebivolol and sotalol in patients ventricular arrhythmias (VA) given its impact on the regulatory adaptive status (RAS). Material and methods. 60 patients with VA of grade I-IV based on the В.Lown grading system, I-II groups based on J.T. Bigger grading system against the background of essential hypertension and/or coronary heart disease took part in the research, they were randomized into two groups for treatment with nebivolol (6,5 ± 2,1 mg/day) and sotalol (166,7 ± 49,4 mg/day). As part of combination therapy, patients were administered lisinopril (13,7 ± 4,5 mg/day and 14,0 ± 4,6 mg/day), acetylsalicylic acid when required (92,9 ± 18,2 mg/day and 95,5 ± 15,1 mg/day), atorvastatin (16,5 ± 4,7 mg/day and 15,7 ± 5,1 mg/day) in addition to nebivolol and sotalol, respectively. Initially and 6 months after therapy, the following was done: quantitative assessment of RAS (by cardio-respiratory synchronism test), echocardiography, triplex scanning of common carotid arteries, treadmill test, six-minute walk test, all-day monitoring of blood pressure and electrocardiogram, subjective assessment of quality of life. Results. Both drug regimens comparably improved structural and functional condition of the heart, increased controlled arterial hypertension, effectively suppressed ventricular arrhythmia, improved the quality of life. Nebivolol positively affected the RAS and increased exercise tolerance more. Conclusion. In patients with VA against the background of essential hypertension and/or coronary heart disease as part of combination therapy the use of nebivolol may be preferable to sotalol due to its positive impact on the RAS.